{
    "clinical_study": {
        "@rank": "85565", 
        "arm_group": [
            {
                "arm_group_label": "LY2605541", 
                "arm_group_type": "Experimental", 
                "description": "Stable dose of LY2605541 (0.2 - 0.8 units per kilogram [U/kg]) administered subcutaneously (SQ) once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen."
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "arm_group_type": "Active Comparator", 
                "description": "Stable dose of insulin glargine (0.2 - 0.8 U/kg) administered SQ once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen."
            }
        ], 
        "brief_summary": {
            "textblock": "This study has two parts. Each participant will receive a daily injection of LY2605541\n      during one treatment period and a daily injection of insulin glargine during the other\n      treatment period. Each treatment period is 3 to 4 weeks and is followed by procedures to\n      look at how the body uses or stores fats while taking each study drug."
        }, 
        "brief_title": "A Study of LY2605541 and Glargine on Fats in Participants With Type 1 Diabetes", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetic for more than 1 year with glycated hemoglobin (HbA1c) of less than\n             8.5%\n\n          -  Otherwise fit and healthy\n\n          -  Non smoker\n\n        Exclusion Criteria:\n\n          -  Taking medication or supplements other than insulin to control diabetes.\n\n          -  Suffered a hypoglycemic event in the last 12 months that required hospitalization or\n             have poor awareness of hypoglycemia\n\n          -  Taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic\n             corticosteroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01771250", 
            "org_study_id": "14871", 
            "secondary_id": "I2R-MC-BIDN"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY2605541", 
                "description": "Daily doses administered SQ.", 
                "intervention_name": "LY2605541", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "description": "Daily doses administered SQ.", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Aarhus", 
                    "country": "Denmark", 
                    "zip": "8000"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus", 
        "overall_contact": {
            "last_name": "This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Denmark: Danish Health and Medicines Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations", 
                "safety_issue": "No", 
                "time_frame": "Day 22 of each treatment period from start of triglyceride metabolism assessment (TMA) procedure (time 0) up to 420 minutes"
            }, 
            {
                "measure": "VLDL-TG Secretion Rate", 
                "safety_issue": "No", 
                "time_frame": "Day 22 of each treatment period from start of TMA procedure (time 0) up to 420 minutes"
            }, 
            {
                "measure": "VLDL-TG Oxidation Rate", 
                "safety_issue": "No", 
                "time_frame": "Day 22 of each treatment period from start of TMA procedure (time 0) up to 420 minutes"
            }, 
            {
                "measure": "VLDL-TG Clearance Rate", 
                "safety_issue": "No", 
                "time_frame": "Day 22 of each treatment period from start of TMA procedure (time 0) up to 420 minutes"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01771250"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}